These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25003616)

  • 21. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.
    Larkins N; Kim S; Craig J; Hodson E
    Arch Dis Child; 2016 Apr; 101(4):404-8. PubMed ID: 26289063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
    Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.
    Sato M; Ito S; Ogura M; Kamei K
    Pediatr Nephrol; 2014 Aug; 29(8):1373-9. PubMed ID: 24599443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab in the treatment of nephrotic syndrome: a systematic review.
    Otukesh H; Hoseini R; Rahimzadeh N; Fazel M
    Iran J Kidney Dis; 2013 Jul; 7(4):249-56. PubMed ID: 23880800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.
    Gulati A; Sinha A; Jordan SC; Hari P; Dinda AK; Sharma S; Srivastava RN; Moudgil A; Bagga A
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2207-12. PubMed ID: 20798255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab in idiopathic nephrotic syndrome: does it make sense?
    Cara-Fuentes G; Kairalla JA; Ishimoto T; Rivard C; Johnson RJ; Garin EH
    Pediatr Nephrol; 2014 Aug; 29(8):1313-9. PubMed ID: 23793923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab treatment for adult patients with focal segmental glomerulosclerosis.
    Ochi A; Takei T; Nakayama K; Iwasaki C; Kamei D; Tsuruta Y; Shimizu A; Shiohira S; Moriyama T; Itabashi M; Mochizuki T; Uchida K; Tsuchiya K; Hattori M; Nitta K
    Intern Med; 2012; 51(7):759-62. PubMed ID: 22466834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment strategies in idiopathic nephrotic syndrome.
    Ulinski T; Aoun B
    Minerva Pediatr; 2012 Apr; 64(2):135-43. PubMed ID: 22495188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapies: Is there a role for rituximab in nephrotic syndrome?
    Feehally J
    Nat Rev Nephrol; 2014 May; 10(5):245-7. PubMed ID: 24614409
    [No Abstract]   [Full Text] [Related]  

  • 32. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope?
    Pradhan M; Furth S
    J Am Soc Nephrol; 2012 Jun; 23(6):975-8. PubMed ID: 22581992
    [No Abstract]   [Full Text] [Related]  

  • 33. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.
    Sellier-Leclerc AL; Belli E; Guérin V; Dorfmüller P; Deschênes G
    Pediatr Nephrol; 2013 Sep; 28(9):1875-9. PubMed ID: 23700173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Childhood nephrotic syndrome--current and future therapies.
    Greenbaum LA; Benndorf R; Smoyer WE
    Nat Rev Nephrol; 2012 Jun; 8(8):445-58. PubMed ID: 22688744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-treatment with high-dose prednisolone after rituximab infusion for childhood-onset steroid-resistant nephrotic syndrome.
    Fujinaga S; Hara T
    Pediatr Nephrol; 2014 Jul; 29(7):1291-2. PubMed ID: 24633445
    [No Abstract]   [Full Text] [Related]  

  • 37. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
    Smith GC
    Pediatr Nephrol; 2007 Jun; 22(6):893-8. PubMed ID: 17310362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
    Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
    Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.
    Tellier S; Brochard K; Garnier A; Bandin F; Llanas B; Guigonis V; Cailliez M; Pietrement C; Dunand O; Nathanson S; Bertholet-Thomas A; Ichay L; Decramer S
    Pediatr Nephrol; 2013 Jun; 28(6):911-8. PubMed ID: 23340857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.